Clinical trials have shown that LAG-3 blockade as a cancer treatment activates APC to promote DCs proliferation and enhances regulatory T cell immunosuppression and antigen cross-presentation to CD8+ T cells, promoting an anti-tumor state [124]. The gene discussed is CD8A; the disease is cancer.